Array pain drug fails to better existing treatment, shares fall

Published August 1, 2012

Array pain drug fails to better existing treatment, shares fall

Filed under: drug treatment news

(Reuters) – Array BioPharma Inc (ARRY.O) said its experimental pain drug did not reduce pain better than the existing standard of care in a mid-stage study, sending its shares down 13 percent in after-market trade. The compound, ARRY-797, reduced pain …
Read more on Reuters

Ampio announces successful Pre-IND meeting with the Ophthalmology Division …

Filed under: drug treatment news

1, 2012 /PRNewswire via COMTEX/ — Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) , a clinical stage biopharmaceutical company developing drugs for the treatment of inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male …
Read more on MarketWatch (press release)

Novartis drug AfinitorR approved by European Commission to treat patients with …

Filed under: drug treatment news

Novartis International AG / Novartis drug AfinitorR approved by European Commission to treat patients with the most common form of advanced breast cancer . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the …
Read more on Reuters

From Twitter:

FibroGen’s FG-3019 Granted U.S. Orphan Drug Designation for the Treatment of Patients with Idiopathic Pulmonary… http://t.co/wrU4ojuT – by EON_Science (EON Science News)

From Twitter:

FibroGen’s FG-3019 Granted U.S. Orphan Drug Designation for the Treatment of Patients with Idiopathic Pulmonary… http://t.co/nkLgmHpC – by BW_Health (BW Health News)

From Twitter:

Researchers investigate drug resistant ovarian cancer to improve clinical treatment: http://t.co/Yp4p1Tih #cancer – by werpurpletweets (The Purple Society)